Vitti Labs, an AATB Accredited Tissue Bank focused on life Science Research, development, and manufacturing, announced today that the U.S. Food and Drug Administration (FDA) has approved their...
Read More »VivaZome licenses University of Adelaide stem cell technology to support development and commercialization of exosome-based therapeutics
VivaZome Therapeutics Pty Ltd and the University of Adelaide today announced that they have entered into a series of agreements encompassing licensing of...
Read More »Aegle Therapeutics Announces $4M Financing to Fund Groundbreaking Stem Cell Exosome Clinical Trial
Aegle’s capital raise will fund the first clinical trial in the U.S. using exosomes isolated from allogeneic mesenchymal stem cells as therapy. Aegle Therapeutics Corp., a first in class biotechnology company isolating extracellular vesicles, including exosomes (“EVs”), secreted by mesenchymal ...
Read More »Avalon GloboCare CEO David Jin to unveil exosome commercialization plan at China confab
Avalon GloboCare announced Thursday that CEO David Jin will unveil the launch of the company’s new commercialization plan for its exosome...
Read More »Stem cell-derived exosomes – an emerging tool for myocardial regeneration
Cardiovascular diseases (CVDs) continue to represent the number one cause of death and disability in industrialized countries. The most severe form of CVD is acute myocardial infarction (AMI), a devastating disease associated with high mortality...
Read More »Aegle Therapeutics receives IND clearance from FDA for stem cell-derived extracellular vesicle therapy
Aegle Therapeutics Corporation, a regenerative medicine company isolating extracellular vesicles (“EVs”) from allogeneic bone marrow derived mesenchymal stem cells (“MSCs”) to treat severe...
Read More »Regeneus reports positive trial results of exosome stem cell technology platform – Progenza
Regeneus, a clinical-stage regenerative medicine company, today announced that the previously reported positive results from its Phase 1 safety trial of Progenza in patients with knee osteoarthritis (OA) have been published in the Journal of Translational Medicine. The STEP trial (Safety, Tolerability ...
Read More »Mining exosomal microRNAs from HiPSC-derived cardiomyocytes for cardiac regeneration
Myocardial infarction is the leading cause of morbidity and mortality worldwide. Recent advances in cardiac regenerative therapy have allowed for novel modalities in replenishing the damaged myocardium. However, poor long-term engraftment and survival of transplanted cells have largely precluded effective ...
Read More »Texas A&M, Celltex team up to research exosomes as Alzheimer’s therapies
Houston-based biotechnology company, Celltex Therapeutics Corporation, and Texas A&M University Health Science Center College of Medicine Institute for Regenerative Medicine today announced an intellectual property license acquisition and research...
Read More »Exosomes released from stem cell patches shown to treat heart attack damage
Human heart muscle patches made from stem cells helped fix damage and improve heart functions in tests with pigs induced with heart attacks. A team at University of Alabama in Birmingham describes the patch and findings from the tests...
Read More »